KAYLA CASTANEDA: Open Payments
NPI 1174773857 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$40,240 in 122 payments from 14 companies in 2025. Trend: 2023 $2,417 · 2024 $6,574 · 2025 $40,240
Speaker / faculty: $13,805Speaker / faculty: $10,761Travel & lodging: $10,414Food & beverage: $3,649Consulting: $1,598Education: $13
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 62 | $21,815 |
| GlaxoSmithKline, LLC. | 30 | $13,732 |
| PFIZER INC. | 2 | $3,205 |
| Globus Medical, Inc. | 4 | $455 |
| Janssen Biotech, Inc. | 2 | $204 |
| Merck Sharp & Dohme LLC | 6 | $160 |
| Daiichi Sankyo Inc. | 2 | $138 |
| Pharmacosmos Therapeutics Inc. | 1 | $122 |
| Regeneron Healthcare Solutions, Inc. | 1 | $121 |
| AstraZeneca Pharmaceuticals LP | 6 | $118 |
Products named: Lenvima, JEMPERLI, ZEJULA, TIVDAK, Senza, RYBREVANT, LYNPARZA, Enhertu.
Industry payments across TX — which companies pay providers there.
